With pride we can announce that our lifesciences team has supported ATB therapeutics from Marche-en-Famenne, Belgium, in its Series A financing round, with a volume of 54mn Euros. The deal was announced on Nov 18, 2024.
ATB has developed technologies that make recombinant immunotoxins producable, and has established a pipeline of highly potent anti-cancer drug candidates. Like other biotech startups, Our team has supported ATB therapeutics from the very first minute, and we are proud that our work has helped it’s excellent team to acquire 3rd party capital.
Another biotech client of ours, SciRhom GmbH, has signed a Series A financing round in July 2024 year, with a volume of 63mn Euros. As a result, among the Biotech startups with the five most valuable series A deals this year in continental Europe, we are representing two:
1. Adcendo - Denmark - 98 million € series A | antibody-drug conjugates
2. Calluna Pharma - Norway - 75 million € series A | immune-related therapies
3. SciRhom - Germany - 63 million € series A | antibody therapies/autoimmune
4. AQEMIA - France - 60 million € series A | AI-enabled drug discovery
5. ATB Therapeutics - Belgium 54 - million € series A | Immunotoxins
(Source: Labiotech)
This development demonstrates the excellence of MHP’s counselling practice, and the value our life sciences team can offer to biotech startup and spinoff clients. It is rewarding to see how our work helps to create value and acquire 3rd pary capital, and in such way help innovative drugs come to the market. Of note, we are currently representing, directly, biotech startup clients in 11 European countries, including Germany, Austria, Spain, Poland, Estonia, France, Belgium, Switzerland, Italy, Norway and the Netherlands.
So, wherever you startup or spinoff is based in Europe, our team is only a phone call away to support you in your IP needs.
